TEST BANK FOR Pharmacotherapeutics for Advanced Practice: A Practical Approach Fifth Edition by Virginia Poole Arcangelo ISBN: 978-1975160593 COMPLETE GUIDE ALL CHAPTERS COVERED 100% VERIFIED A+ GRADE ASSURED!!!!!NEW LATEST UPDATE!!!!!

, lOM cn cn oARc P


SD| cn 3013804




cn cn cn
lOM oARc PSD| 3013804




Chapter 1 Issues for the Practitioner in Drug Therapy
cn cn cn cn cn cn cn cn




MULTIPLE CHOICE cn




1. Nurse practitioner prescriptive authority is regulated by:
cn c n c n cn cn c n



A. The National Council of State Boards of Nursing
cn cn cn cn cn cn cn



B. The U.S. Drug Enforcement Administration
cn cn cn cn



C. The State Board of Nursing for each state
cn cn cn cn cn cn cn



D. The State Board of Pharmacy
cn cn cn cn




ANS: C c n PTS: 1 cn




2. Physician Assistant (PA) prescriptive authority is regulated by:
cn c n c n cn cn cn c n



A. The National Council of State Boards of Nursing
cn cn cn cn cn cn cn



B. The U.S. Drug Enforcement Administration
cn cn cn cn



C. The State Board of Nursing
cn cn cn cn



D. The State Board of Medical Examiners
cn cn cn cn cn




ANS: D c n PTS: 1 cn




3. Clinical judgment in prescribing includes:
cn cn cn cn



A. Factoring in the cost to the patient of the medication prescribed
cn cn cn cn cn cn cn cn cn cn



B. Always prescribing the newest medication available for the disease process
cn cn cn cn cn cn cn cn cn



C. Handing out drug samples to poor patients
cn cn cn cn cn cn



D. Prescribing all generic medications to cut costs cn cn cn cn cn cn




ANS: A c n PTS: 1 cn




4. Criteria for choosing an effective drug for a disorder include:
cn cn cn cn cn cn cn cn cn



A. Asking the patient what drug they think would work best for them
cn cn cn cn cn cn cn cn cn cn cn



B. Consulting nationally recognized guidelines for disease management
cn cn c n cn c n c n



C. Prescribing medications that are available as samples before writing a prescription
cn cn cn cn cn cn cn cn cn cn



D. Following U.S. Drug Enforcement Administration (DEA) guidelines for p
cn cn cn cn cn cn cn c n



rescribing
ANS: B c n PTS: 1 cn




5. Nurse practitioner practice may thrive under health-care reform due to:
cn cn cn cn cn cn cn cn cn



A. The demonstrated ability of nurse practitioners to control costs and improve patient o
cn cn cn cn cn cn cn cn cn cn cn c n



utcomes
B. The fact that nurse practitioners will be able to practice independently
cn cn cn cn cn cn cn cn cn cn



C. The fact that nurse practitioners will have full reimbursement under health-
cn cn cn cn cn cn cn cn cn cn



care reform c n



D. The ability to shift accountability for Medicaid to the state level
cn cn cn cn c n cn cn cn cn cn




ANS: A c n PTS: 1 cn

, lOM cn cn
oARc P


SD| cn3013804




Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
cn cn cn cn cn cn




MULTIPLE CHOICE cn




1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to p
cn cn c n cn cn cn cn cn cn cn cn cn cn



rescribing because: c n



A. Distribution of drugs to target tissue may be affected cn cn cn cn cn cn cn cn



B. The solubility of the drug will not match the site of absorption
cn cn cn cn cn cn cn cn cn cn cn



C. There will be less free drug available to generate an effect
cn cn cn cn cn cn cn cn cn cn



D. Drugs bound to albumin are readily excreted by the kidney
cn cn cn cn cn cn cn cn cn




ANS: A c n PTS: 1 cn




2. Drugs that have a significant first-pass effect:
cn cn cn cn cn cn



A. Must be given by the enteral (oral) route only
cn cn cn cn cn cn cn cn



B. Bypass the hepatic circulation cn cn cn



C. Are rapidly metabolized by the liver and may have little if any desired action
cn cn cn cn cn cn c n cn cn cn cn cn cn



D. Are converted by the liver to more active and fat-soluble forms
cn cn cn cn cn cn cn cn cn cn




ANS: C c n PTS: 1 cn




3. The route of excretion of a volatile drug will likely be:
cn cn cn cn cn cn cn cn cn cn



A. The kidneys cn



B. The lungs cn



C. The bile and feces cn cn cn



D. The skin cn




ANS: B c n PTS: 1 cn




4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the cn c n c n cn cn cn cn cn c n cn c n cn cn



drug. Storage reservoirs:
cn cn



A. Assure that the drug will reach its intended target tissue
cn cn cn cn cn cn cn cn cn



B. Are the reason for giving loading doses
cn cn cn cn cn cn



C. Increase the length of time a drug is available and active
cn cn cn cn cn cn cn cn cn cn



D. Are most common in collagen tissues
cn cn cn cn cn




ANS: C c n PTS: 1 cn




5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
cn cn cn cn cn cn cn cn cn cn cn cn cn cn



A. Propensity to go to the target receptor cn cn cn cn cn cn



B. Biological half-life c n



C. Pharmacodynamics
D. Safety and side effects cn cn cn




ANS: B c n PTS: 1 cn




6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the p
cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn



rescription. This is considered a loading dose. A loading dose:
cn cn cn c n cn c n c n cn c n



A. Rapidly achieves drug levels in the therapeutic range
cn cn cn cn cn cn cn



B. Requires four to five half-lives to attain cn cn cn cn cn cn



C. Is influenced by renal function
cn cn cn cn

, cn cn
lOM oARc P


cn
SD| 3013804




D. Is directly related to the drug circulating to the target tissues
cn cn cn cn cn cn cn cn cn cn




ANS: A c n PTS: c n c n 1

7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic
cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn



effect is the:
cn cn



A. Minimum adverse effect level cn cn cn



B. Peak of action cn cn



C. Onset of action cn cn



D. Therapeutic range c n




ANS: C c n PTS: 1 cn




8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
cn cn cn cn cn cn cn cn cn cn cn cn



A. When the drug has a wide therapeutic range
cn cn cn cn cn cn cn



B. When the drug will be administered for a short time only
cn cn cn cn cn cn cn cn cn cn



C. When there is a high correlation between the dose and saturation of receptor sites
cn cn cn cn cn cn cn cn cn cn cn cn c n



D. To determine if a drug is in the therapeutic range
cn cn cn cn cn cn cn cn cn




ANS: D c n PTS: 1 cn




9. A laboratory result indicates the peak level for a drug is above the minimum toxic c
cn cn cn cn cn cn cn cn cn cn cn cn cn cn cn



oncentration. This means that the: cn cn cn cn



A. Concentration will produce therapeutic effects c n c n cn c n



B. Concentration will produce an adverse response cn cn cn cn cn



C. Time between doses must be shortened
cn cn cn cn cn



D. Duration of action of the drug is too long cn cn cn cn cn cn cn cn




ANS: B c n PTS: 1 cn




10. Drugs that are receptor agonists may demonstrate what property?
cn cn cn cn cn cn cn cn



A. Irreversible binding to the drug receptor site cn cn cn cn cn c n



B. Up-regulation with chronic use cn cn cn



C. Desensitization or down-regulation with continuous use cn c n c n cn cn



D. Inverse relationship between drug concentration and drug action
cn cn cn cn cn cn cn




ANS: C c n PTS: 1 cn




11. Drugs that are receptor antagonists, such as beta blockers, may cause:
cn cn cn cn cn cn cn cn cn cn



A. Down-regulation of the drug receptor cn cn cn cn



B. An exaggerated response if abruptly discontinued
cn cn cn cn c n



C. Partial blockade of the effects of agonist drugs
cn cn cn cn cn cn cn



D. An exaggerated response to competitive drug agonists
cn cn cn cn cn cn




ANS: B c n PTS: 1 cn




12. Factors that affect gastric drug absorption include:
cn cn cn cn cn cn



A. Liver enzyme activity cn cn



B. Protein-binding properties of the drug molecule cn cn cn cn c n



C. Lipid solubility of the drug cn cn cn cn



D. Ability to chew and swallow cn cn cn cn




ANS: C c n PTS: 1 cn